Skip to content

Rigel Pharmaceuticals RIGL Shares Reserved for Future Issuance Under Stock Plans

Shares Reserved for Future Issuance Under Stock Plans at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
18.6M
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
29.2M+7.7%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's shares reserved for future issuance under stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's shares reserved for future issuance under stock plans?
Rigel Pharmaceuticals (RIGL) reported shares reserved for future issuance under stock plans of 702.3K in Q1 2026.
What does shares reserved for future issuance under stock plans mean?
This represents the total number of common shares authorized and set aside for future issuance to employees and directors under equity compensation plans. It provides insight into the potential future dilution of existing shareholders. Investors monitor this to assess the firm's long-term incentive structure.